Mechanistic and Biomarker Studies on Cancer Progression and Taxane Resistance
癌症进展和紫杉烷耐药性的机制和生物标志物研究
基本信息
- 批准号:8878425
- 负责人:
- 金额:$ 1.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-02-15 至 2016-08-14
- 项目状态:已结题
- 来源:
- 关键词:3-Phosphoinositide Dependent Protein Kinase-1AKT Signaling PathwayAdhesionsAdverse effectsApoptosisApoptoticBCL2 geneBindingBiological AssayBiological MarkersBiopsyBreastBreast Cancer CellBreast Cancer ModelBreast Cancer TreatmentBreast CarcinomaCalciumCalpainCancer PatientCancer cell lineCause of DeathCell DeathCell LineCell ProliferationCellsClinicalClinical ResearchClinical assessmentsDataDiseaseDoseERBB2 geneEpidermal Growth FactorEstrogen ReceptorsFDA approvedFunctional disorderFutureHealthHomeostasisHumanImageImmunoblottingImmunohistochemistryIn VitroIncidenceIndividualInterventionLithiumMalignant NeoplasmsMedicalMedical HistoryModelingMolecularMolecular TargetMonitorNeoplasm MetastasisNeuronsNeurosecretory SystemsOutcomePaclitaxelPathway interactionsPatient CarePatientsPharmaceutical PreparationsPhenotypePhosphatidylinositolsPhosphotransferasesPlayPost-Translational Protein ProcessingProcessPrognostic MarkerProteinsProto-Oncogene Proteins c-aktRelapseResistanceRiskRoleSignal PathwaySignal TransductionTaxane CompoundTechnologyTherapeuticTherapeutic InterventionTimeTissue MicroarrayValidationWomanbasecalpain inhibitorchemotherapeutic agentclinical applicationcohortin vitro Assayinhibitor/antagonistlymph nodesmalignant breast neoplasmmigrationmortalitynew therapeutic targetnoveloutcome forecastpreventprognosticreceptorresearch studyresponsesensorstable cell linetaxanetreatment strategytumortumor progression
项目摘要
DESCRIPTION (provided by applicant): The incidence of breast cancer is high, with 1 in 8 women in the U.S. developing this disease over the course of their lifetime. Taxanes are potent chemotherapeutic agents that are a standard component of early and metastatic breast cancer treatment strategies. Despite major therapeutic advances, progression of tumors and taxane resistance continue to be major clinical problems that promote breast cancer mortality. The clinical application of biomarkers have greatly reduced the mortality rates associated with breast cancer; however, there is an urgent need for novel biomarkers that can more effectively identify patients who are 1) at risk for advanced breast cancer progression or 2) resistant to taxane therapy. Using a candidate approach, we sought to investigate the role of neuronal calcium sensor-1 (NCS-1) in breast cancer. NCS-1 (a novel binding partner of the taxane, paclitaxel) has been shown to act as a survival factor in neurons by activating the Phosphoinositide 3- kinase (PI3K)/ Protein Kinase B (AKT) signaling pathway. Our central hypothesis is that NCS-1 promotes breast cancer progression and taxane resistance by altering cancer signaling networks. This hypothesis is based on the functional characterization of NCS-1, in neuronal and neuroendocrine models, as well as our preliminary data. Using immunohistochemistry (IHC) and our novel Automated Quantitative Analysis (AQUA) technology, we quantified the expression of NCS-1 in 619 cases of primary breast carcinomas. We found that NCS-1 was expressed in a cohort of breast cancer patients and significantly correlates with poor clinical outcome independent of Estrogen Receptor (ER), Human Epidermal Growth Factor 2 Receptor (HER-2), and lymph node status. The objectives of our study are to 1) investigate the role of NCS-1 in the molecular mechanisms governing breast cancer progression and taxane resistance and to 2) assess the clinical utility of NCS-1 as a novel predictive/ prognostic breast cancer biomarker. Elucidating the role of NCS-1 in breast cancer progression and taxane resistance may broaden our understanding of these processes and establish NCS-1 as a novel molecular target for future therapeutic intervention. Furthermore, findings from our study may validate NCS-1 as a novel predictive/ prognostic breast cancer biomarker, which may ultimately increase breast cancer survival through individualization of patient care.
描述(由申请人提供):乳腺癌的发病率很高,美国八分之一的妇女在其一生中患上这种疾病。紫杉烷是有效的化学治疗剂,是早期和转移性乳腺癌治疗策略的标准组成部分。尽管有重大的治疗进展,但肿瘤和抗紫杉烷耐药性的进展仍然是促进乳腺癌死亡率的主要临床问题。生物标志物的临床应用大大降低了与乳腺癌相关的死亡率。但是,迫切需要新型的生物标志物,可以更有效地识别出1)患乳腺癌进展风险的患者,或2)耐紫杉烷治疗。使用候选方法,我们试图研究神经元钙传感器-1(NCS-1)在乳腺癌中的作用。 NCS-1(紫杉烷,紫杉醇的新型结合伴侣)已通过激活磷酸肌醇3-激酶(PI3K)/蛋白激酶B(AKT)信号通路来充当神经元的生存因子。我们的中心假设是NCS-1通过改变癌症信号网络促进乳腺癌的进展和紫杉烷耐药性。该假设基于NCS-1,神经内分泌模型以及我们的初步数据的功能表征。使用免疫组织化学(IHC)和我们的新型自动定量分析(Aqua)技术,我们在619例原发性乳腺癌病例中量化了NCS-1的表达。我们发现NCS-1在乳腺癌患者的队列中表达,并且与临床结果较差,与雌激素受体(ER),人表皮生长因子2受体(HER-2)和淋巴结状态无关。我们研究的目标是1)研究NCS-1在控制乳腺癌进展和抗紫杉烷耐药性的分子机制中的作用,以及2)评估NCS-1作为一种新型的预测/预后/预后乳腺癌生物标志物的临床实用性。阐明NCS-1在乳腺癌进展和抗紫杉烷耐药性中的作用可能会扩大我们对这些过程的理解,并确立NCS-1作为未来治疗干预的新分子靶标。此外,我们研究的发现可能会验证NCS-1作为一种新型的预测/预后乳腺癌生物标志物,这可能最终通过患者护理的个性化增加乳腺癌的生存。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lauren Michelle Moore其他文献
Lauren Michelle Moore的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lauren Michelle Moore', 18)}}的其他基金
Mechanistic and Biomarker Studies on Cancer Progression and Taxane Resistance
癌症进展和紫杉烷耐药性的机制和生物标志物研究
- 批准号:
8994279 - 财政年份:2014
- 资助金额:
$ 1.6万 - 项目类别:
Mechanistic and Biomarker Studies on Cancer Progression and Taxane Resistance
癌症进展和紫杉烷耐药性的机制和生物标志物研究
- 批准号:
8652824 - 财政年份:2014
- 资助金额:
$ 1.6万 - 项目类别:
相似国自然基金
基于“阳虚阴结”理论探讨甘草干姜汤通过Sirt1调控PI3K/Akt信号通路抑制肺成纤维细胞增殖干预RA-ILD的机制研究
- 批准号:82305166
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
TSPAN9激活ITGB1/FAK/AKT信号通路促进系膜细胞表型转化在糖尿病肾病中的作用机制研究
- 批准号:82300819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
玉屏风散调节PI3K/AKT/mTOR信号通路校正Tfh细胞功能增强体液免疫应答治疗小儿反复呼吸道感染的机制研究
- 批准号:82305313
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
- 批准号:82370979
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
生物3D打印组织工程骨通过PI3K-AKT信号通路诱导MSCs成骨分化促进骨缺损修复的效应及机制研究
- 批准号:82302700
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction
EphB4-ephrinB2 相互作用对受辐射 HNSCC 中 Tregs 跨内皮迁移的调节
- 批准号:
10415869 - 财政年份:2021
- 资助金额:
$ 1.6万 - 项目类别:
The role of cannabinoids in the regulation of the blood brain barrier in the context of NeuroHIV and anti-retroviral therapy
大麻素在 NeuroHIV 和抗逆转录病毒治疗背景下调节血脑屏障的作用
- 批准号:
10536689 - 财政年份:2021
- 资助金额:
$ 1.6万 - 项目类别: